| Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos (t) ide reverse … JR Arribas, PM Girard, R Landman, J Pich, J Mallolas, ... The Lancet Infectious Diseases 15 (7), 785-792, 2015 | 194 | 2015 |
| Remdesivir for severe coronavirus disease 2019 (COVID-19) versus a cohort receiving standard of care SA Olender, KK Perez, AS Go, B Balani, EG Price-Haywood, NS Shah, ... Clinical Infectious Diseases 73 (11), e4166-e4174, 2021 | 182 | 2021 |
| Sexualized drug use (Chemsex) is associated with high-risk sexual behaviors and sexually transmitted infections in HIV-positive men who have sex with men: data from the U-SEX … A González-Baeza, H Dolengevich-Segal, I Pérez-Valero, A Cabello, ... AIDS Patient Care and STDs 32 (3), 112-118, 2018 | 144 | 2018 |
| Impact of late presentation of HIV infection on short-, mid-and long-term mortality and causes of death in a multicenter national cohort: 2004–2013 P Sobrino-Vegas, S Moreno, R Rubio, P Viciana, JI Bernardino, ... Journal of Infection 72 (5), 587-596, 2016 | 99 | 2016 |
| Bone mineral density and inflammatory and bone biomarkers after darunavir–ritonavir combined with either raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults … JI Bernardino, A Mocroft, PW Mallon, C Wallet, J Gerstoft, C Russell, ... The lancet HIV 2 (11), e464-e473, 2015 | 92 | 2015 |
| Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial A Carr, B Grund, J Neuhaus, A Schwartz, JI Bernardino, D White, ... HIV medicine 16, 137-146, 2015 | 65 | 2015 |
| Changes in cardiovascular disease risk factors with immediate versus deferred antiretroviral therapy initiation among HIV‐positive participants in the START (Strategic Timing … JV Baker, S Sharma, AC Achhra, JI Bernardino, JR Bogner, D Duprez, ... Journal of the American Heart Association 6 (5), e004987, 2017 | 61 | 2017 |
| Human immunodeficiency virus/hepatitis C virus coinfection in Spain: prevalence and patient characteristics J Berenguer, A Rivero, I Jarrín, MJ Núñez, MJ Vivancos, M Crespo, ... Open forum infectious diseases 3 (2), ofw059, 2016 | 61 | 2016 |
| Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial A Esteban-Cantos, J Rodríguez-Centeno, P Barruz, B Alejos, ... The lancet HIV 8 (4), e197-e205, 2021 | 59 | 2021 |
| Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study S Serrano-Villar, J Martínez-Sanz, R Ron, A Talavera-Rodríguez, ... The lancet HIV 7 (8), e565-e573, 2020 | 53 | 2020 |
| Prevalence of abnormal anal cytology and high-grade squamous intraepithelial lesions among a cohort of HIV-infected men who have sex with men E Sendagorta, P Herranz, H Guadalajara, JI Bernardino, JM Viguer, ... Diseases of the Colon & Rectum 57 (4), 475-481, 2014 | 53 | 2014 |
| Immediate versus deferred switching from a boosted protease inhibitor–based regimen to a dolutegravir-based regimen in virologically suppressed patients with high … JM Gatell, L Assoumou, G Moyle, L Waters, M Johnson, P Domingo, J Fox, ... Clinical Infectious Diseases 68 (4), 597-606, 2019 | 49 | 2019 |
| Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir E Martinez, A Gonzalez‐Cordon, E Ferrer, P Domingo, E Negredo, ... Hiv Medicine 15 (6), 330-338, 2014 | 46 | 2014 |
| Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as … S Lambert-Niclot, EC George, A Pozniak, E White, C Schwimmer, ... Journal of Antimicrobial Chemotherapy 71 (4), 1056-1062, 2016 | 41 | 2016 |
| Remdesivir versus standard-of-care for severe coronavirus disease 2019 infection: an analysis of 28-day mortality SA Olender, TL Walunas, E Martinez, KK Perez, A Castagna, S Wang, ... Open forum infectious diseases 8 (7), ofab278, 2021 | 40 | 2021 |
| Unified European support framework to sustain the HIV cascade of care for people living with HIV including in displaced populations of war-struck Ukraine M Vasylyev, A Skrzat-Klapaczyńska, JI Bernardino, O Săndulescu, ... The Lancet HIV 9 (6), e438-e448, 2022 | 39 | 2022 |
| Chems4EU: chemsex use and its impacts across four European countries in HIV‐positive men who have sex with men attending HIV services GG Whitlock, K Protopapas, JI Bernardino, A Imaz, A Curran, C Stingone, ... HIV medicine 22 (10), 944-957, 2021 | 39 | 2021 |
| Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial E Martinez, A Gonzalez-Cordon, E Ferrer, P Domingo, E Negredo, ... Clinical Infectious Diseases 60 (5), 811-820, 2015 | 37 | 2015 |
| HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction JV Baker, J Neuhaus, D Duprez, M Freiberg, JI Bernardino, AD Badley, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 60 (2), 128-134, 2012 | 37 | 2012 |
| Human papillomavirus mRNA testing for the detection of anal high‐grade squamous intraepithelial lesions in men who have sex with men infected with HIV E Sendagorta, MP Romero, JI Bernardino, MJ Beato, M Alvarez‐Gallego, ... Journal of Medical Virology 87 (8), 1397-1403, 2015 | 35 | 2015 |
